Invitrogen™ CD85j (ILT2) Monoclonal Antibody (HP-F1), NovaFluor™ Yellow 590, eBioscience™, Invitrogen™

CD85j, also known as a member of the leukocyte immunoglobulin-like receptor (LIR) family, is a single transmembrane glycoprotein with a long cytoplasmic domain containing four immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs signal through interactions with SHP-1, transducing negative signals that inhibit immune response stimulation. CD85j is expressed on myeloid cells such as monocytes and dendritic cells, as well as on subsets of lymphoid cells including NK, T, and B cells. The expression of CD85j is correlated with leukemias such as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). On CD8+ cells, CD85j expression is associated with effector cell function and plays a significant role in viral infections, including HIV, Epstein-Barr virus, and cytomegalovirus (CMV). CD85j binds to MHC class I molecules, including HLA-G, A, F, B27, E, and F, on antigen-presenting cells. The receptor helps control inflammatory responses and cytotoxicity, focusing the immune response and limiting autoreactivity. CD85j belongs to the subfamily B class of LIR receptors, which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and multiple transcript variants encoding different isoforms have been identified for this gene. Its gene is located in a cluster at chromosomal region 19q13.4.